Treatment with recombinant HSPB1 has shown translational potential, reducing the paralytic symptoms when injected intraperitoneally in the experimental autoimmune encephalomyelitis mouse model, alongside decreased levels of the inflammatory cytokines IL-2, IL-6, and IFNγ (89). Here, HSPB1 is linked to experimental autoimmune encephalomyelitis.